Abstract:In this issue of the Journal, Verhoeven and colleagues (1) further document the association between depressive and anxiety disorders and shorter leukocyte telomere length (LTL), an indicator of cellular aging. The researchers, reporting data from 2,936 participants in the Netherlands Study of Depression and Anxiety (NESDA) (2), observed that participants with remitted and with current depressive and anxiety disorders show shorter LTL than never-affected controls across baseline and 6-year follow-up. The researchers controlled for lifestyle and somatic health variables known also to affect telomere length. As illustrated in Figure 2 of their report, the longitudinal course of illness over 6 years (e.g., new onset, persistent remission, relapse, chronic) was not associatedwith differences in LTL attrition rates. The investigators conclude that short LTL could be either a long-term consequence (“imprint”) of depression and anxiety or a biomarker of an underlying vulnerability factor for these commonmental disorders. The studywas not designed to address this conundrum conclusively. What is new about this study is its focus on the longitudinal course of illness and LTL attrition. In a previous crosssectional report published in Molecular Psychiatry and addressing depression and accelerated cellular aging (3), the investigators observed significantly shorter LTL in both currently depressed (5,461 base pairs) and remitted (5,459 base pairs) patients compared with controls (5,541 base pairs). These differences in length were estimated to be the equivalent of 4–6 years of accelerated physiologic—not chronologic—aging. As in the current study, the large sample size of NESDA participants permitted control for potential confounders such as smoking, body mass index, alcohol use, and physical activity. In the Molecular Psychiatry report, the investigators reported evidence of a dose-response gradient: both depression severity and duration of depressive symptoms in the previous 4 years were associated with shorter telomeres. That relationship appears not to have been confirmed in the current longitudinal study, which offered a much finer-grained analysis of illness course. The researchers haveposited that prior depression leaves a telomere scar even after the episode is over—that is, an “imprint” of past exposure to depression. They raise further questions of profound public health and clinical moment, for example, does telomere shortening contribute to medical comorbidities commonly seen in depressed patients, such as heart disease, diabetes, obesity, and cancer? Finally, they point out that how telomere length relates to treatment response is still unclear, although in the current report LTL was not found to be associated with cumulative antidepressant exposure. In order to place these observations in further context, this commentary will first summarize contemporary understanding of what telomeres are, their function, and their relationship to cellular aging. Secondly, the commentary will offer several observations emerging in the literature of geroscience that account for mechanisms of telomere shortening and the relevance of these mechanisms to common mental disorders like depression. Finally, to recapture a clinical perspective, recent observations relating depression treatment to reductions inmortality secondary to cancerwill be summarized.

Telomere length and mitochondrial DNA copy number in bipolar disorder: identification of a subgroup of young individuals with accelerated cellular aging

Accelerated epigenetic aging and mitochondrial DNA copy number in bipolar disorder

Decreased telomere length in a subgroup of young individuals with bipolar disorders: replication in the FACE-BD cohort and association with the shelterin component POT1

Accelerated Leukocyte Telomere Erosion in Schizophrenia: Evidence from the Present Study and a Meta-Analysis

Analysis of telomere length and the relationship with neurocognitive functions in euthymic bipolar disorder: A cross-sectional pilot study

Analysis on in vitro effect of lithium on telomere length in lymphoblastoid cell lines from bipolar disorder patients with different clinical response to long-term lithium treatment

Shortening of telomere length may be associated with inflammatory cytokine levels in patients with bipolar disorder

Telomere length and its associations with mental disorders, age and genetic risk for mental disorders

Mitochondrial DNA copy number is significantly increased in bipolar disorder patients and is correlated with long-term lithium treatment

Telomere length in psychiatric disorders: Is it more than an ageing marker?

Telomere Biology in Mood Disorders: An Updated, Comprehensive Review of the Literature

Downregulation in components of the mitochondrial electron transport chain in the postmortem frontal cortex of subjects with bipolar disorder.

Telomere Attrition: A Window Into Common Mental Disorders and Cellular Aging.

Leukocyte mitochondrial DNA copy number in blood is not associated with major depressive disorder in young adults.

[Telomeres in the brain cortex of depressive patients]

Systemic inflammation, oxidative damage and neurocognition predict telomere length in a transdiagnostic sample stratified by global DNA methylation levels

Mitochondrial Biomarkers and Metabolic Syndrome in Bipolar Disorder

The theory of bipolar disorder as an illness of accelerated aging: Implications for clinical care and research

Increased circulating cell-free mitochondrial DNA in plasma of first-diagnosed drug-naïve bipolar disorder patients: A case-control and 4-week follow-up study

Pilot study of circulating cell-free mitochondrial DNA in relation to brain structure in youth bipolar disorder

Leukocyte Telomere Length and Mitochondrial DNA Copy Number in Treatment-Resistant Depression and Response to Electroconvulsive Therapy: A Pilot Longitudinal Study